ag panaloko

Radical Jaguar rebrand and new logo sparks ire online NEW YORK (AP) — A promotional video for a rebrand of British luxury car brand Jaguar is being criticized online for showing models in brightly colored outfits — and no car. The rebrand, which includes a new logo, is slated to launch Dec. 2 during Miami Art Week, when the company will unveil a new electric model. But Jaguar Land Rover, a unit of India’s Tata Motors Ltd., has been promoting it online. The Jaguar brand is in the middle of a transition to going all-electric. “Copy Nothing,” marketing materials read. “We’re here to delete the ordinary. To go bold. To copy nothing.” Trump has promised again to release the last JFK files. But experts say don’t expect big revelations DALLAS (AP) — The nation is set to mark 61 years since President John F. Kennedy was assassinated as his motorcade passed through downtown Dallas on Nov. 22, 1963. Even after over six decades, conspiracy theories about what happened that day still swirl and the desire to follow every thread of information hasn’t waned. President-elect Donald Trump made promises over the summer that if reelected he would declassify the remaining records. At this point, only a few thousand of millions of pages of records related to the assassination have yet to be fully released. And those who have studied what's been released so far say that the public shouldn’t anticipate any earth-shattering revelations even if the remaining files are declassified. Bitcoin is at the doorstep of $100,000 as post-election rally rolls on NEW YORK (AP) — Bitcoin is jumping again, rising above $98,000 for the first time Thursday. The cryptocurrency has been shattering records almost daily since the U.S. presidential election, and has rocketed more than 40% higher in just two weeks. It's now at the doorstep of $100,000. Cryptocurrencies and related investments like crypto exchange-traded funds have rallied because the incoming Trump administration is expected to be more “crypto-friendly.” Still, as with everything in the volatile cryptoverse, the future is hard to predict. And while some are bullish, other experts continue to warn of investment risks. NFL issues security alert to teams and the players' union following recent burglaries The NFL has issued a security alert to teams and the players’ union following recent burglaries involving the homes of Chiefs stars Patrick Mahomes and Travis Kelce. In a memo obtained by The Associated Press, the league says homes of professional athletes across multiple sports have become “increasingly targeted for burglaries by organized and skilled groups.” Law enforcement officials noted these groups target the homes on days the athletes have games. Players were told to take precautions and implement home security measures to reduce the risk of being targeted. Some of the burglary groups have conducted extensive surveillance on targets. Penn State wins trademark case over retailer's use of vintage logos, images PHILADELPHIA (AP) — Penn State has won a closely watched trademark fight over an online retailer’s use of its vintage logos and images. A Pennsylvania jury awarded Penn State $28,000 in damages earlier this week over products made and sold by the firms Vintage Brand and Sportswear Inc. Penn State accused the firms of selling counterfeit clothing and accessories. The defendants said their website makes clear they are not affiliated with Penn State. At least a dozen other schools have sued the defendants on similar grounds, but the Pennsylvania case was the first to go to trial. Defense lawyers declined to comment on the verdict and whether they planned an appeal. Has a waltz written by composer Frederic Chopin been discovered in an NYC museum? NEW YORK (AP) — A previously unknown musical work written by composer Frederic Chopin appears to have been found in a library in New York City. The Morgan Library & Museum says the untitled and unsigned piece is the first new manuscript of the Romantic era virtuoso to be discovered in nearly a century. Robinson McClellan, the museum’s curator, says he stumbled across the work in May while going through a collection brought to the Manhattan museum years earlier. He worked with outside experts to verify the document's authenticity. But there’s debate whether the waltz is an original Chopin work or merely one written in his hand. Volcano on Iceland's Reykjanes Peninsula erupts for the 7th time in a year GRINDAVIK, Iceland (AP) — A volcano on the Reykjanes Peninsula in southwestern Iceland is spewing lava from a fissure in its seventh eruption since December. Iceland's seismic monitors said the eruption started with little warning late Wednesday and created a long fissure but looked to be smaller than eruptions in August and May. Around 50 houses were evacuated after the Civil Protection agency issued the alert, along with guests at the famous Blue Lagoon resort, according to the national broadcaster. The repeated eruptions over the past year have caused damage to the town of Grindavík and forced people to relocate. Australian teen and British woman who drank tainted alcohol in Laos have died, bringing toll to 5 VIENTIANE, Laos (AP) — An Australian teenager and a British woman have died after drinking tainted alcohol in Laos in what Australia’s prime minister said was every parent’s nightmare. Officials earlier said an American and two Danish tourists also had died following reports that multiple people had been sickened in town popular with backpackers. Australian Prime Minister Anthony Albanese told Parliament that 19-year-old Bianca Jones had died after being evacuated from Vang Vieng, Laos, for treatment in a Thai hospital. Her friend, also 19, remains hospitalized in Thailand. Later Thursday, Britain said a British woman also died and the media in the U.K. identified her as 28-year-old Simone White. US ahead in AI innovation, easily surpassing China in Stanford's new ranking The U.S. leads the world in developing artificial intelligence technology, surpassing China in research and other important measures of AI innovation, according to a newly released Stanford University index. There’s no surefire way to rank global AI leadership but Stanford researchers have made an attempt by measuring the “vibrancy” of the AI industry across a variety of dimensions, from how much research and investment is happening to how responsibly the technology is being pursued to prevent harm. Following the U.S. and China were the United Kingdom, India and the United Arab Emirates. Pop star Ed Sheeran helps favorite soccer team sign player before getting on stage with Taylor Swift It turns out British pop star Ed Sheeran is also good at recruiting soccer players. Sheeran is a minority shareholder at English soccer team Ipswich Town and it needed his help over the summer to get a player to join the club. Ipswich CEO Mark Ashton tells a Soccerex industry event in Miami: “Ed jumped on a Zoom call with him at the training ground, just before he stepped on stage with Taylor Swift. Hopefully that was a key part in getting the player across the line.” Ashton didn’t disclose the player in question, saying only: “He’s certainly scoring a few goals.”ag panaloko 。

LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference in San Francisco in 2020, the forum has become a significant platform for advancing cell and gene therapy (CGT). This year's move to Europe underscores GenScript's commitment to driving the global CGT innovation and fostering international collaboration. "Putting patients first" is the underlying principle driving progress in the pharmaceutical industry and the inspiration behind this year's forum. "All our efforts in creating this platform for open dialogue and international collaboration in the CGT industry ultimately aim to address patient needs," said Jesse Chen, VP of Government Affairs and Corporate Communications at GenScript, in a pre-event interview. The forum brought together global thought leaders from academia, industry, and investment sectors in CGT to explore the theme "Unlock the Full Potential of Cell and Gene Therapies." Discussions focused on the latest breakthroughs, technological innovations, and future trends, offering multi-dimensional perspectives on advancing the CGT industry to benefit more patients. The forum was moderated by Dr. Shawn Wu, President of European Division at GenScript. Sherry Shao, Rotating CEO of GenScript, delivered the opening remarks, emphasizing: "Every step forward in CGT, every innovation, is ultimately about serving patients better." She reaffirmed GenScript's commitment to driving innovation in CGT and collaborating with global partners to bring life-changing therapies to more patients worldwide. The forum featured two keynote sessions with distinguished speakers: Dr. Miguel Forte, President of the International Society for Cell & Gene Therapy (ISCT), ARM Board Member, and CEO of Kiji Therapeutics, and Dr. James Wilson, a pioneer in gene therapy and President & CEO of Gemma Biotherapeutics (GEMMABio); Founder and Advisor of Scout Bio, Passage Bio, iECURE; Executive Chair at Franklin Biolabs. Their thought-provoking presentations not only deepened attendees' understanding of the field but also offered valuable insights into the future of cell and gene therapy (CGT). Dr. Forte's delivered a keynote titled "Status and Expectations for Cell and Gene Therapy in 2024 and Beyond," focused on the transformative potential of cell therapy. He delved into gene editing, in vivo therapies, and the challenges and opportunities associated with regulatory approval. He emphasized the importance of understanding the long-term nature of cell therapy development and the significance of global collaboration. Dr. Wilson's keynote, "The Case for Rare Diseases in Genetic Medicine Development," He emphasized the importance of gene therapy for rare diseases and elaborated on the commercialization challenges of gene therapy products and discussed issues encountered in clinical development, such as technological shortcomings, the complexity of clinical trials, and production challenges. Dr. Wilson also emphasized the importance of patient advocacy and social media in promoting drug accessibility and raising public awareness. Additionally, he highlighted the need to focus on reimbursement mechanisms and achieve a balance between innovation and the resource utilization of health authorities. In addition to the compelling keynote speeches, the forum featured a range of dynamic interactive sessions, including three roundtable discussions and a fireside chat. These sessions attracted significant attention, offering lively debates and actionable insights that resonated with the audience. The success of CAR-T therapies in hematologic malignancies has revealed the vast potential of cell therapies. Now, the focus is on extending these breakthroughs to broader patient populations, including those with solid tumors and autoimmune diseases, which have become a shared goal across the industry. During the "Technology Innovation and Breakthroughs in Cell Therapy" roundtable, Mr. Stephen Hansen, Director of Biopharma Intelligence at BioCentury, moderated a vibrant discussion featuring leaders such as Dr. Ying Huang, CEO of Legend Biotech, Dr. Reagan Jarvis, CEO and Co-founder of Anocca, Dr. Pascal Touchon, Chairman of the Board at Atara Biotherapeutics, Mr. Jason Foster, CEO and Executive Director of Ori Biotech, and Dr. Biao Zheng, CEO of BRL Medicine. They approached the topic from the patient's perspective, highlighting the exceptional efficacy of CAR-T therapy. The experts also shared promising clinical data on the use of CAR-T drugs for autoimmune diseases and expressed high hopes for their future development. They emphasized that developing more patient-friendly, user-friendly CAR-T therapies is critical for increasing patient acceptance. Additionally, expanding production capacity, improving product accessibility, and ensuring product safety are urgent priorities. Collaboration with medical centers is key to developing commercially viable products. As innovative therapies continue to be researched, the potential applications of CAR-T therapy will be further unlocked, offering patients more treatment options. Driven by technological breakthroughs, significant progress has been made in gene therapy and mRNA vaccine fields, with applications expanding rapidly. However, the production of these therapies is complex, particularly when it comes to the choice, production, and optimization of delivery vectors, which have a profound impact on their development. In the roundtable discussion on "Progress in Gene Therapy and mRNA Vaccine," hosted by Ms. Kristina Cornish, Partner at Pinsent Masons, London & European and UK Patent Attorney, leading researchers including Mr. Deividas Pazeraitis, Senior Scientist at AstraZeneca, Dr. Karim Benabdellah, Principal Investigator at GENYO, Dr. Maelle Quere, Scientist at Sanofi, Dr. Vincenzo Di Cerbo, Lead Technical Scientist at Cell and Gene Therapy Catapult, and Dr. Lumeng Ye, Director of Novel therapeutic materials at GenScript; all agreed that long-term delivery efficiency and technological bottlenecks remain key challenges in translating innovations into clinical applications. The discussion focused on the technological trends and innovative developments in the clinical applications of gene editing, the topics cover the selection of viral vectors (VP), non-viral vectors (NVP), lipid nanoparticles (LNP), and virus-like particles (VLP) in different application areas, the innovative developments in gene therapy and mRNA vaccines, as well as an analysis of the advantages and disadvantages of mRNA vaccines compared to traditional vaccines, along with development trends and application prospects. They also provided a comprehensive review of the progress from technological innovation to clinical application in this field and unanimously agreed that long-term delivery technology and in vitro cell line technology remain key challenges. The development process for CGT is highly complex and personalized, and these characteristics are seen as major challenges to the continuous supply of these therapies. In the subsequent roundtable discussion on "CMC Challenges with Developing & Manufacturing Cell and Gene Therapies," led by Dr. Qingyu Cao, Senior Director & head of European Business Development at ProBio, and panelists are Dr. Jim Faulkner, CEO of JDB BioConsulting, Mr. Arindam Mitra, CMC Director at Leucid Bio, Dr. Dima Al-hadithi, Director at Minaret Consulting Limited, and Ms. Ming Ewe, CEO of Smarter Biotech Solutions, engaged in lively discussions on key issues such as production process standardization, quality control, and viral vector production. The discussion presented practical strategies and solutions, providing important references for the widespread application of CGT. The experts emphasized the need for early planning of CMC and regulatory strategies in the context of accelerated approval processes, ensuring that product development and quality control can proceed in parallel. They also highlighted the importance of selecting the right CDMO partners to support full collaboration. Furthermore, they suggested that efforts should begin early in the R&D phase, with active communication with regulatory agencies to enhance the understanding of new technologies and methods, and a clear supply chain map should be created to ensure stable supply. Regarding future trends, the experts believe that AI technology will play a key role in optimizing gene therapy design, improving production efficiency, and advancing automation processes. They are confident that, with ongoing technological advancements and increasing market competition, the price of CGT therapies will gradually decrease, making them a widely accessible treatment option. R&D and manufacturing in the cell and gene therapy field require substantial financial investment, with long return cycles, making funding pressure a key constraint on industry growth. In the closing fireside chat, "Navigating the Future of CGT: Insights from Investors," was moderated by Dr. Kelly Shi, Senior VP & Research Analys at Jefferies LLC, Dr. Josh Resnick, Senior Managing Director at RA Capital Management, and Mr. Ping Shek, Managing Director at Stifel's Investment Banking Division, discussed the investment landscape for CGT. The speakers shared their investment insights in the CGT field, reviewing the evolution of the sector from its early boom to the current adjustment phase. When discussing investment strategies, the participants highlighted key considerations such as addressing patient needs, reducing uncertainty in research and development as well as manufacturing, and increasing commercialization success rates. They also emphasized the need for continued innovation in reducing manufacturing costs. Regarding the investment trend in CGT, despite market fluctuations, signs of recovery began to emerge in 2023, indicating a positive outlook for future capital inflows. Currently, investment behavior is becoming more cautious, and the market is steadily moving toward normalization. Furthermore, the evolving regulatory environment and changes in reimbursement policies have had a profound impact on investment decisions. Addressing infrastructure development and therapy accessibility is viewed as a core driver for the sustained growth of the industry. The GenScript Biotech Global Forum concluded successfully with engaging discussions from experts and scholars. This event brought together global leaders from the biopharmaceutical industry, who shared valuable experiences and unique insights, injecting fresh momentum into the continued development and innovation of the global cell and gene therapy sector. Moving forward, GenScript Biotech remains committed to building more open and inclusive collaboration platforms to drive innovation and progress in the field of cell and gene therapy. As an annual event, the GenScript Global Forum will continue to uphold its core focus of "patient-centered" goals, advancing scientific innovation and market applications in cell and gene therapies, bringing greater hope for a healthier global future. About GenScript Biotech Corporation GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacture. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and Cell Therapy Business Unit. GenScript accelerates scientific discovery and therapeutic breakthrough with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 5060 employees. As of June 30, 2024, over 100,000 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world. For more information, please visit GenScript Biotech's official website https://www.genscript.com View original content: https://www.prnewswire.com/news-releases/the-genscript-biotech-global-forum-makes-a-strong-debut-in-europe-highlighting-breakthroughs-in-cell-and-gene-therapy-development-302313220.html SOURCE GenScript Biotech Corporation

From the season’s outset, Timberwolves coach Chris Finch said Minnesota would leave itself the flexibility to close games with whatever lineup the coaching staff felt was needed to secure a victory. ADVERTISEMENT Sometimes, he noted, he’d get the choice right. Surely, there would be other times when he wouldn’t. “Hopefully, I do way more than I don’t,” Finch said this week. Sunday evening, however, was a checkmark in the “not right” column, at least based off the result. The Timberwolves didn’t score in the final 4:47 of their loss to Golden State. Finch said this week that Mike Conley’s inclusion in the closing lineup would’ve added organization to the equation. But he was quick to add that, with the ill-advised shots Anthony Edwards was taking, may not have mattered. ADVERTISEMENT Finch also reiterated what he said after the game, that Nickeil Alexander-Walker was playing “so well,” so he was hesitant to take him off the floor. “Maybe the other thing I could’ve done was go small,” Finch said, “but we’ve not really done that a ton.” That was the cry of many Wolves’ followers on social media on Sunday. Minnesota has proven rather inept at late-game offense when Conley isn’t on the floor. But all recognized Alexander-Walker had also earned the opportunity to close. You certainly won’t take Edwards off the floor in those situations, and the Wolves wanted Jaden McDaniels on the floor to guard Steph Curry. That left Julius Randle and Rudy Gobert as the only options to take off the court in favor of Conley, and that would’ve left Minnesota small. And, as Finch noted, the Wolves simply haven’t gone small this season. Like, at all. None of Naz Reid, Randle or Gobert have played more than 17 minutes this season without another big man next to him. ADVERTISEMENT It’s not something the Wolves practice, either. McDaniels said he’s only repped minutes at the four in practice when one of the bigs have been unavailable. Still, Finch said it wasn’t that he was “uncomfortable” rolling out a small-ball look Sunday. “But I worry a lot about rebounding. We struggle to rebound with our bigger lineups, at times. So, I know our smaller lineups have really struggled,” Finch said. “That’s some of the reason not to go small is really rebounding issues. But I think our guys are comfortable playing in all different combinations. But I haven’t really thought about going small, necessarily.” ADVERTISEMENT Indeed, Minnesota is just 12th in the NBA this season in defensive rebounding rate, grabbing 71.3% of opposing missed shots. The glass was especially an issue Sunday, as Golden State grabbed 14 offensive rebounds that led to 19 second-chance points. But it’s worth noting many of those came by guards in situations in which size was no factor on the play. McDaniels said he’s comfortable playing any position, including the power forward slot. And Minnesota certainly has the wing depth to roll out more small ball lineups if the situation ever called for it. There could be a playoff matchup that does just that, though Finch noted it could also go the other direction where the Wolves’ advantage would be to lean bigger. Versatility rules come April and May. But the Wolves don’t seem overly urgent to trot out any small-ball looks just to see how they perform at this juncture in the campaign. ADVERTISEMENT “Usually, it’s better with Naz at the four (than me),” McDaniels said. There is, however, at least one proponent of doing a little experimenting: Conley. “I think (small ball) kind of promotes a different level of spacing and speed to the game. You’re going to have to rely on guard-guard situations, guard pick and rolls,” Conley said. “Maybe me setting the screen and roll, Just creating different advantages for ourselves, as opposed to our typical offense or typical flow of things. I would love to see it, maybe — see how it works.” ADVERTISEMENT ______________________________________________________ This story was written by one of our partner news agencies. Forum Communications Company uses content from agencies such as Reuters, Kaiser Health News, Tribune News Service and others to provide a wider range of news to our readers. Learn more about the news services FCC uses here .None

Dynavax to Present at the 7th Annual Evercore HealthCONx ConferenceSEATTLE , Nov. 26, 2024 /PRNewswire/ -- Nordstrom, Inc. (NYSE: JWN) today reported third quarter net earnings of $46 million , or earnings per diluted share ("EPS") of $0.27 , and earnings before interest and taxes ("EBIT") of $83 million . Excluding a charge related to accelerated technology depreciation, the Company reported adjusted EBIT of $97 million and adjusted EPS of $0.33 .[1] For the third quarter ended November 2, 2024, net sales increased 4.6 percent versus the same period in fiscal 2023, and total Company comparable sales increased 4.0 percent. Gross merchandise value ("GMV") increased 5.3 percent. Anniversary Sale timing, with one week shifting from the third quarter to the second quarter, had a negative impact of approximately 100 basis points on net sales compared with 2023. During the quarter, Nordstrom banner net sales increased 1.3 percent and comparable sales increased 4.0 percent. Net sales for Nordstrom Rack increased 10.6 percent and comparable sales increased 3.9 percent. "The continued sales growth across the company and strong gross margin in the third quarter indicate our team's focus and efforts are working," said Erik Nordstrom , chief executive officer of Nordstrom, Inc. "Our customers have a lot of choices, and our results give us encouragement that we're on the right path. Looking ahead, we'll continue to improve our shopping experience as we strive to maintain the positive momentum we've worked towards all year." In the third quarter, women's apparel and active had double-digit growth, and shoes, men's apparel and kids were up mid to high single-digits, versus 2023. Growth in women's apparel, shoes and men's apparel accelerated sequentially from the second quarter. "Our third quarter results demonstrate that our strategic focus on curating a compelling brand assortment is resonating with customers," said Pete Nordstrom , president of Nordstrom, Inc. "Our actions throughout this year have led to this moment, and we feel well-positioned for a successful holiday season and look forward to helping our customers celebrate the moments that matter. I'm grateful to our dedicated team for consistently delivering the high level of service our customers have come to expect from Nordstrom." As previously announced, the board of directors declared a quarterly cash dividend of $0.19 per share, payable on December 18, 2024, to shareholders of record at the close of business on December 3, 2024. THIRD QUARTER 2024 SUMMARY STORES UPDATE To date in fiscal 2024, the Company has opened 23 stores: City Location Square Footage (000s) Timing of Opening Nordstrom Rack Pinole, CA Pinole Vista Crossing 23 March 7, 2024 Snellville, GA Presidential Markets 35 March 7, 2024 Kennesaw, GA Barrett Place 25 March 21, 2024 Macedonia, OH Macedonia Gateway 28 April 11, 2024 Gilroy, CA Gilroy Crossing 25 April 25, 2024 Jacksonville Beach, FL South Beach Regional 30 May 2, 2024 Queen Creek, AZ Queen Creek Marketplace 28 May 16, 2024 Elk Grove, CA The Ridge Elk Grove 25 May 30, 2024 Wheaton, IL Danada Square East 29 May 30, 2024 Oceanside, CA Pacific Coast Plaza 32 June 6, 2024 Bay Shore, NY Gardiner Manor Mall 24 June 13, 2024 San Antonio, TX Bandera Pointe 24 September 5, 2024 Franklin, TN Cool Springs Market 24 September 5, 2024 San Mateo, CA Bridgepointe Shopping Center 36 September 12, 2024 San Diego, CA Clairemont Town Square 25 September 19, 2024 Mooresville, NC Mooresville Crossing 28 September 26, 2024 Houston, TX Meyerland Plaza 34 September 26, 2024 Mason, OH Deerfield Towne Center 30 October 3, 2024 Raleigh, NC Triangle Town Place 32 October 10, 2024 Fort Myers, FL Bell Tower 31 October 17, 2024 Noblesville, IN Hamilton Town Center 25 October 17, 2024 Omaha, NE Village Pointe 30 October 24, 2024 Tarzana, CA Village Walk 25 November 1, 2024 The Company has also announced plans to open the following stores: City Location Square Footage (000s) Timing of Opening Nordstrom Rack Davis, CA The Davis Collection 25 Spring 2025 Matthews, NC Sycamore Commons 25 Spring 2025 Geneva, IL Randall Square 25 Spring 2025 Manalapan Township, NJ Manalapan Commons 26 Spring 2025 Apple Valley, MN Fischer Marketplace 30 Spring 2025 Houston, TX Westchase Shopping Center 30 Spring 2025 Morrisville, NC Park West Village 25 Spring 2025 Coral Springs, FL Pine Ridge Square 31 Fall 2025 Surprise, AZ Prasada North 26 Fall 2025 Holbrook, NY The Shops at SunVet 27 Fall 2025 Hyannis, MA The Landing at Hyannis 25 Fall 2025 Prosper, TX The Gates of Prosper 26 Fall 2025 Melbourne, FL The Avenue Viera 24 Fall 2025 Meridian, ID The Village at Meridian 25 Fall 2025 Lakeland, FL Lakeside Village 30 Fall 2025 Sarasota, FL Sarasota Pavilion 27 Spring 2026 The Company had the following store counts as of quarter-end: November 2, 2024 October 28, 2023 Nordstrom Nordstrom 93 93 Nordstrom Local service hubs 6 6 ASOS | Nordstrom — 1 Nordstrom Rack Nordstrom Rack 280 258 Last Chance clearance stores 2 2 Total 381 360 Gross store square footage 26,874,000 26,305,000 During the third quarter, the Company closed one Nordstrom Rack store. FISCAL YEAR 2024 OUTLOOK The Company updated its financial outlook for fiscal 2024, which reflects the estimated accelerated technology depreciation impacts expected in the fourth quarter of fiscal 2024: CONFERENCE CALL INFORMATION The Company's senior management will host a conference call to provide a business update and to discuss third quarter 2024 financial results and fiscal 2024 outlook at 4:45 p.m. EST today. To listen to the live call online and view the speakers' prepared remarks and the conference call slides, visit the Investor Relations section of the Company's corporate website at investor. nordstrom .com . An archived webcast with the speakers' prepared remarks and the conference call slides will be available in the Quarterly Results section for one year. Interested parties may also dial 201-689-8354. A telephone replay will be available beginning approximately three hours after the conclusion of the call by dialing 877-660-6853 or 201-612-7415 and entering Conference ID 13750079, until the close of business on December 3, 2024. ABOUT NORDSTROM At Nordstrom, Inc. (NYSE: JWN), we exist to help our customers feel good and look their best. Since starting as a shoe store in 1901, how to best serve customers has been at the center of every decision we make. This heritage of service is the foundation we're building on as we provide convenience and true connection for our customers. Our interconnected model enables us to serve customers when, where and how they want to shop – whether that's in-store at more than 350 Nordstrom, Nordstrom Local and Nordstrom Rack locations or digitally through our Nordstrom and Rack apps and websites. Through it all, we remain committed to leaving the world better than we found it. Certain statements in this press release contain or may suggest "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involves risks and uncertainties that could cause results to be materially different from expectations. The words "will," "may," "designed to," "outlook," "believes," "should," "targets," "anticipates," "assumptions," "plans," "expects" or "expectations," "intends," "estimates," "forecasts," "guidance" and similar expressions identify certain of these forward-looking statements. The Company also may provide forward-looking statements in oral statements or other written materials released to the public. All statements contained or incorporated in this press release or in any other public statements that address such future events or expectations are forward-looking statements. Important factors that could cause actual results to differ materially from these forward-looking statements are detailed in the Company's Annual Report on Form 10-K for the fiscal year ended February 3, 2024, our Form 10-Q for the fiscal quarter ended May 4, 2024 , our Form 10-Q for the fiscal quarter ended August 3, 2024 and our Form 10-Q for the fiscal quarter ended November 2, 2024 , to be filed with the SEC on or about December 5, 2024 . In addition, forward-looking statements contained in this release may be impacted by the actual outcome of events or occurrences related to the Company's announcement of the exploration of possible avenues to enhance shareholder value, including consideration by a special committee of the board of directors of a proposal brought forward by members of the Nordstrom family to take the Company private. These forward-looking statements are not guarantees of future performance and speak only as of the date made, and, except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, new information or future circumstances. In addition, the actual timing, price, manner and amounts of future share repurchases, if any, will be subject to the discretion of our board of directors, contractual commitments, market and economic conditions and applicable Securities and Exchange Commission rules. This earnings release includes references to websites, website addresses and additional materials, including reports and blogs, found on those websites. The content of any websites and materials named, hyperlinked or otherwise referenced in this earnings release are not incorporated by reference into this earnings release or in any other report or document we file with the SEC, and any references to such websites and materials are intended to be inactive textual references only. The information on those websites is not part of this earnings release. NORDSTROM, INC. CONSOLIDATED STATEMENTS OF EARNINGS (unaudited; amounts in millions, except per share amounts) Quarter Ended Nine Months Ended November 2, 2024 October 28, 2023 November 2, 2024 October 28, 2023 Net sales $3,347 $3,200 $10,353 $9,926 Credit card revenues, net 117 120 339 347 Total revenues 3,464 3,320 10,692 10,273 Cost of sales and related buying and occupancy costs (2,156) (2,080) (6,760) (6,488) Selling, general and administrative expenses (1,225) (1,163) (3,680) (3,466) Canada wind-down costs — 25 — (284) Earnings before interest and income taxes 83 102 252 35 Interest expense, net (26) (24) (79) (78) Earnings (loss) before income taxes 57 78 173 (43) Income tax (expense) benefit (11) (11) (45) 43 Net earnings $46 $67 $128 $— Earnings per share: Basic $0.28 $0.41 $0.78 $— Diluted $0.27 $0.41 $0.76 $— Weighted-average shares outstanding: Basic 164.6 162.0 164.0 161.5 Diluted 169.8 163.6 168.1 161.5 Percent of net sales: Gross profit 35.6 % 35.0 % 34.7 % 34.6 % Selling, general and administrative expenses 36.6 % 36.3 % 35.5 % 34.9 % Earnings before interest and income taxes 2.5 % 3.2 % 2.4 % 0.4 % NORDSTROM, INC. CONSOLIDATED BALANCE SHEETS (unaudited; amounts in millions) November 2, 2024 February 3, 2024 October 28, 2023 Assets Current assets: Cash and cash equivalents $397 $628 $375 Accounts receivable, net 544 334 322 Merchandise inventories 2,780 1,888 2,626 Prepaid expenses and other current assets 311 286 392 Total current assets 4,032Before the Bell: ASX to edge higher, US stocks reverse early advance - The Australian Financial Review

New York Jets interim coach Jeff Ulbrich said Aaron Rodgers “absolutely” will remain the team's starting quarterback and start Sunday against the Seattle Seahawks. Rodgers, who turns 41 next Monday, has been hampered at times during the Jets' 3-8 start by various injuries to his left leg, including a sore knee, sprained ankle and balky hamstring. Ulbrich said Monday the quarterback came back from the team's bye-week break ready to go. “All I can say, and you'd have to ask Aaron if he's fully healthy, but he's better off today than he's been as of late,” Ulbrich said. "So he's definitely feeling healthier than he has probably for the past month. A healthy Aaron Rodgers is the Aaron Rodgers we all love. “So, I'm excited about what that looks like.” NFL Network reported on Sunday that Rodgers, who missed all but four snaps last season with a torn left Achilles tendon , has declined having medical scans on his injured leg so he can continue to play. “I have not been informed of that, either way,” Ulbrich said. Rodgers suffered what NFL Network reported was a “significant” hamstring injury against Denver in Week 4. He then sprained his left ankle against Minnesota in London a week later. The four-time MVP has not been able to consistently move around during games as he has in the past, when extending plays and making things happen on the run became such a big part of his game. Rodgers said leading into New York's 28-27 loss to Indianapolis last Sunday that it was the healthiest he felt in a while. But he struggled against the Colts, finishing 22 of 29 for 184 yards after a brutally slow start during which he went 9 of 13 for just 76 yards. The Athletic reported last week that owner Woody Johnson broached the idea during a meeting with the coaching staff of having the banged-up Rodgers sit after the Jets' loss to Denver in Week 4. With Rodgers' struggles and perhaps compromised health the past few games, a hot debate on social media and sports talk shows during the past week has been whether the quarterback should take a seat in favor of Tyrod Taylor. But when asked if there has been any talk of shutting down Rodgers, Ulbrich replied flatly: “There has not.” In a follow-up question, the interim coach was asked if Rodgers will, in fact, be the Jets' starting quarterback at home Sunday against the Seahawks. “Absolutely,” Ulbrich said. He added that he didn't feel the need to sit down with Rodgers and address all the reports and chatter outside the facility. “No, I feel like we are on the same page,” the coach said. Last week, Ulbrich said he and his staff would take “a deep dive” into what the team could do better after losing seven of its past eight and being on the verge of missing the postseason for the 14th consecutive year. Ulbrich opted not to make any changes to the coaching responsibilities of his staff and he will continue to run the defense as the coordinator. He also said there would not be any personnel changes coming out of the bye, barring injuries. “But definitely, we created a really clear vision of where we need to improve and found some things,” Ulbrich said. “Obviously, you find the things that you’re not doing well, you need to improve upon them, but then also found some some things that I think we can really build upon. So I was excited in both ways.” Johnson fired general manager Joe Douglas last Tuesday, six weeks after he also dismissed coach Robert Saleh. On Monday, the team announced it would be assisted by The 33rd Team , a football media, analytics and consulting group founded by former Jets GM Mike Tannenbaum, in its searches for a general manager and coach. Ulbrich insisted that isn't creating an awkward situation for him, in particular, as he and his staff focus on the present while the organization begins planning for the future. “In all honesty, it’s not at all,” Ulbrich said. “My singular focus is just finishing the season off the right way, playing a brand of football we’re all proud of, myself included. And that starts with Seattle.” LB C.J. Mosley said he's “progressing” in his return from a herniated disk in his neck, but is still uncertain about his availability for Sunday. Mosley said Monday was the first time he put on a helmet since the injury occurred during pregame warmups against New England on Oct. 27. ... Ulbrich said the team is still evaluating LT Tyron Smith, who missed the game against Indianapolis with a neck ailment. AP NFL: https://apnews.com/hub/nfl

Republicans won big in a relatively high-turnout election. How did it happen?Special counsel Jack Smith said he is dropping his election subversion case against President-elect Donald Trump, seeking the case’s dismissal in a court filing. Rep. Dan Goldman (D-NY) reacts.None